IL258494A - Rational combined therapy for cancer treatment - Google Patents

Rational combined therapy for cancer treatment

Info

Publication number
IL258494A
IL258494A IL258494A IL25849418A IL258494A IL 258494 A IL258494 A IL 258494A IL 258494 A IL258494 A IL 258494A IL 25849418 A IL25849418 A IL 25849418A IL 258494 A IL258494 A IL 258494A
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination therapy
rational combination
rational
Prior art date
Application number
IL258494A
Other languages
English (en)
Hebrew (he)
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL258494A publication Critical patent/IL258494A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL258494A 2015-10-05 2018-04-04 Rational combined therapy for cancer treatment IL258494A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05
PCT/US2016/055594 WO2017062520A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL258494A true IL258494A (en) 2018-05-31

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258494A IL258494A (en) 2015-10-05 2018-04-04 Rational combined therapy for cancer treatment

Country Status (14)

Country Link
US (1) US20180280397A1 (enExample)
EP (1) EP3359196B1 (enExample)
JP (1) JP7132848B2 (enExample)
KR (1) KR20180058824A (enExample)
CN (1) CN108472376A (enExample)
AU (1) AU2016336351A1 (enExample)
BR (1) BR112018006572A2 (enExample)
CA (1) CA3000851A1 (enExample)
EA (1) EA201890623A1 (enExample)
IL (1) IL258494A (enExample)
MA (1) MA47474A (enExample)
MX (1) MX2018004112A (enExample)
TW (1) TW201722422A (enExample)
WO (1) WO2017062520A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
US20240371465A1 (en) * 2023-05-02 2024-11-07 National Central University Method, system, and computer readable medium for post-translational modifications detection
CN116813622A (zh) * 2023-05-19 2023-09-29 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337275A4 (en) 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
CN108752280A (zh) 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
AU2010303343B2 (en) 2009-10-07 2015-11-19 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as HSP90 inhibitors
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
CA2832099C (en) 2011-04-05 2019-07-09 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN104081203B (zh) 2011-07-08 2018-07-31 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
CA2921571C (en) 2013-08-16 2022-04-05 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
AU2015259173B2 (en) 2014-05-13 2019-09-05 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same

Also Published As

Publication number Publication date
MA47474A (fr) 2019-12-25
WO2017062520A1 (en) 2017-04-13
AU2016336351A1 (en) 2018-05-10
JP2018537519A (ja) 2018-12-20
EP3359196A1 (en) 2018-08-15
MX2018004112A (es) 2018-06-20
EP3359196B1 (en) 2022-03-16
EA201890623A1 (ru) 2018-09-28
TW201722422A (zh) 2017-07-01
JP7132848B2 (ja) 2022-09-07
KR20180058824A (ko) 2018-06-01
BR112018006572A2 (pt) 2018-10-09
CN108472376A (zh) 2018-08-31
CA3000851A1 (en) 2017-04-13
US20180280397A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
IL256224B (en) Combined therapy for cancer treatment
IL254705A0 (en) Combination therapy for cancer
IL258521A (en) Combination of treatments for cancer treatment
PT3033086T (pt) Terapia de combinação para o tratamento de cancro
IL255060A0 (en) Combined treatment for cancer
IL267795A (en) Combined treatment for cancer
SG11201609770TA (en) Combination therapies for the treatment of cancer
EP3258965A4 (en) Combination therapy for cancer treatment
SI3473263T1 (sl) Kombinirani pripravki za zdravljenje raka
IL259996A (en) Combinations for cancer treatment
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL257073A (en) Combined therapies for cancer treatment
LT3458052T (lt) Vėžio kombinuotas gydymas
EP3226901A4 (en) Combination therapy for treatment of cancer
EP3185884A4 (en) Combination therapy for treatment of cancer
IL258494A (en) Rational combined therapy for cancer treatment
IL266993A (en) Combined therapy for cancer treatment
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
GB201519734D0 (en) Cancer therapy
IL259097A (en) Combination therapy for cancer
IL253642A0 (en) Combined treatment for cancer
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy